1
|
Wang J, Xing X, Li Q, Zhang G, Wang T, Pan H, Li D. Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion? Ther Adv Med Oncol 2020; 12:1758835920940948. [PMID: 32754231 PMCID: PMC7378714 DOI: 10.1177/1758835920940948] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Accepted: 06/16/2020] [Indexed: 12/19/2022] Open
Abstract
Cholangiocarcinoma (CCA) is a refractory cancer with limited treatment options
and poorly understood molecular mechanisms underlying tumor development. The
most effective treatment is surgical resection; however, patients are highly
prone to recurrence. Moreover, considering that most patients are diagnosed in
advanced stages, treatment options are restricted to palliative care, which
results in poor prognosis. Due to the limited effect of chemotherapy and
radiotherapy, targeted therapy is becoming a hot topic in the field of biliary
cancer treatment. The fibroblast growth factor/fibroblast growth factor receptor
(FGF/FGFR) signaling pathway involves a variety of key biological processes for
cell survival, differentiation, and metabolism. Next-generation sequencing data
mining has shown that high levels of FGF/FGFR expression are associated with
reduced overall survival (OS) in CAA, which indicates that the FGF/FGFR pathway
may be an effective target for CAA treatment. This paper reviews the effect of
FGF/FGFR signaling on CCA from onset to treatment and highlights the promise of
FGF/FGFR signaling pathway inhibitors for targeting CCA.
Collapse
Affiliation(s)
- Jing Wang
- Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Xiaokang Xing
- Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Qijun Li
- Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Ge Zhang
- Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Tao Wang
- Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Hongming Pan
- Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Da Li
- Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Number 3, East Qingchun Rd, Hangzhou, Zhejiang 310016, China
| |
Collapse
|